Get started
Author

Ana Paula Lacerda

Observed institution: AbbVie (United States)
ORCID: 0000-0002-0122-4183
Observed ORCID: 0000-0002-0122-4183
OpenAlex ID: A5000775613
Upadacitinib Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy
2024 · Jean-Frédéric Colombel, Tadakazu Hisamatsu, et al. · Clinical Gastroenterology and Hepatology · 32
Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn’s disease: 2-year results from the U-ENDURE Long-Term Extension study
2025 · Edward V Loftus, Jr, Geert D’Haens, et al. · Journal of Crohn s and Colitis · 10
PDF
111 - Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results From a Randomized Phase 3 U- Excel Study
2023 · Edward V. Loftus, Jean-Frederic Colombel, et al. · Gastroenterología y Hepatología · 2
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn’s Disease
2025 · Marla C Dubinsky, Geert D’Haens, et al. · Inflammatory Bowel Diseases
PDF
Content Validity and Psychometric Evaluation of the Crohn’s Symptom Severity (CSS) Questionnaire in Patients with Moderately to Severely Active Crohn’s Disease
2024 · Edouard Louis, Wan-Ju Lee, et al. · Advances in Therapy
Resíduos Vítreos: Um Estudo Nas Vidraçarias Do Município De Sousa-pb
2017 · Ana Paula Lacerda, Lindemberg Lima da Silva, et al.
Works count: 6
Citation count: 44
H-index: 2
I10-index: 2
Year
Topic
Type